Could a designer probiotic tame IBD Flare-Ups?
NCT ID NCT07318753
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a specially selected probiotic (LR607) in 300 people with mild-to-moderate ulcerative colitis, a form of inflammatory bowel disease. The probiotic is designed to boost a natural gut pathway (NOD2) that helps control inflammation. The goal is to see if adding LR607 to standard treatment can improve symptoms and reduce disease activity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Hospital of Southern Medical University
Shenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill tame inflammatory bowel disease? early safety trial begins
- Can a mediterranean diet and Time-Restricted eating tame gut inflammation?
- Could early lipid screening in High-Risk kids prevent future heart attacks?
- Two-Drug cocktail aims to tame stubborn Crohn's disease
- Dutch hospital data reveals hidden patterns in IBD treatment
- Acupuncture points may signal hidden disease activity